Skip to main
ALEC

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 0%
Sell 25%
Strong Sell 0%

Bulls say

Alector Inc is developing promising therapies targeting neurodegeneration, highlighted by its novel approach utilizing the transferrin receptor (TfR) for enhanced brain delivery and systemic uptake. The robust early clinical pipeline, particularly with lead programs like AL137, AL050, and ADP064-ABC, represents significant potential due to their alignment with larger indications and the likelihood of generating positive proof-of-concept data. Furthermore, the differentiated platform shows substantial brain uptake and safety signals, bolstering the prospects for clinical success and potential shareholder value.

Bears say

Alector Inc's stock outlook has turned negative due to the failure of its INFRONT-3 trial for latozinemab, which did not meet its primary endpoint, thus highlighting significant translational biology risks alongside previous negative outcomes. Concerns surrounding the efficiency of PGRN transport and its implications for the company's therapeutic approach further exacerbate investment risks, particularly regarding the potential failures of key drug candidates AL001, AL002, and AL101 in clinical studies and regulatory approvals. The overall valuation assessment, based on a discounted cash flow analysis, incorporates a considerable risk of negative readouts from ongoing trials and possible unexpected side effects, raising the uncertainty of achieving projected commercial revenues.

Alector Inc (ALEC) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 4 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.